Kaitlyn D’Onofrio

DocwireNews

In addition to known risk factors, including older age and certain comorbidities, disease activity and specific disease-modifying antirheumatic drugs (DMARDs) may be tied to COVID-19 mortality risk in patients with rheumatic diseases, according to a study.&ldquo;We found that moderate/high disease activity was significantly associated with COVID-19-related death, confirming recent recommendations regarding the importance of disease control in rheumatic diseases in the COVID-19 era,&rdquo; the researchers reported. &ldquo;Overall, compared with methotrexate monotherapy, most DMARDs were not associated with higher odds of death, although rituximab and sulfasalazine were notable exceptions.&rdquo;They collected data from the COVID-19 Global Rheumatology Alliance (C19-GRA), an observational, physician-reported registry that kicked off on March 24, 2020, and includes data voluntarily reported by <a href="https://www.docwirenews.com/docwire-pick/rheumatology-picks/4-reasons-to-see-a-rheumatologist/">rheumatologists</a>. The present study evaluated data collected on or before July 1, 2020. The main outcome was COVID-19-related death. Covariates used in multivariable logistic regression models were age, sex, smoking status, comorbidities, rheumatic disease diagnosis, disease activity, and medications. Patients were also analyzed based on their specific rheumatic disease.Final analysis included 3,729 patients with a mean age of 57 years; most patients were female (68%). Overall, 390 patients died (10.5%). Older age, compared to age &le;65 years, was independently associated with COVID-19-related mortality (age 66-75 years: odds ratio [OR], 3.00; 95% confidence interval [CI], 2.13-4.22; age &gt;75 years: OR, 6.18; 95% CI, 4.47-8.53). Other factors independently associated with <a href="https://www.docwirenews.com/docwire-pick/rheumatology-picks/1-in-3-patients-with-autoimmune-diseases-uncertain-about-covid-19-vaccine/">COVID-19</a>-related mortality were male sex (OR, 1.46; 95% CI, 1.11-1.91); hypertension combined with cardiovascular disease (OR, 1.89; 95% CI, 1.31-2.73), chronic lung disease (OR, 1.68; 95% CI, 1.26-2.25), and prednisolone-equivalent dosage &gt;10 mg/day, compared to no glucocorticoid intake (OR, 1.69; 95% CI, 1.18-2.41.Compared to remission/low disease activity, patients with moderate/high disease activity had a higher risk of COVID-19-related death (OR, 1.87; 95% CI, 1.27-2.77). When compared to receiving methotrexate monotherapy, treatments associated with COVID-19-related death were rituximab (OR, 4.04; 95% CI, 2.32-7.03); sulfasalazine (OR, 3.60; 95% CI, 1.66-7.78); immunosuppressants including azathioprine, cyclophosphamide, ciclosporin, mycophenolate, or tacrolimus (OR, 2.22; 95% CI, 1.43-3.46); and not receiving any DMARD (OR, 2.11; 95% CI, 1.48-3.01). No correlations were observed between other synthetic/biological DMARDs and COVID-19-related death.The study was published in <a href="https://ard.bmj.com/content/early/2021/01/26/annrheumdis-2020-219498">Annals of the Rheumatic Diseases</a>.&ldquo;Among people with rheumatic disease, COVID-19-related death was associated with known general factors (older age, male sex and specific comorbidities) and disease-specific factors (disease activity and specific medications). The association with moderate/high disease activity highlights the importance of adequate disease control with DMARDs, preferably without increasing glucocorticoid dosages. Caution may be required with rituximab, sulfasalazine and some immunosuppressants,&rdquo; the researchers concluded.

MarkAlain Déry, DO

The Significant Danger Measles Pose for Unvaccinated Children

Infectious Disease

Andrew Moreno

Antithrombotic Care in Hemophilia: A Summary of Multi-Organizational Clinical Practice Guidance

Hemophilia

James Tumlin, MD

Joel M. Topf, MD, FACP

Proteinuria Remission With Sparsentan in FSGS

NKF Spring Clinical Meetings 2025

Latest News

Disease Activity, DMARDs May Affect COVID-19 Death Risk in Patients With Rheumatic Disease

COVID-19

In addition to known risk factors, including older age and certain comorbidities, disease activity and specific disease-modifying antirheumatic drugs (DMARDs) may be tied to ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe